Recombinant RSV (Palivizumab Biosimilar) anticorps

N° du produit ABIN7200664

Cet anticorps anti-RSV (Palivizumab Biosimilar) est un anticorps Souris Monoclonal détectant RSV (Palivizumab Biosimilar) dans FACS et in vivo. Adapté pour Humain.

Aperçu rapide pour Recombinant RSV (Palivizumab Biosimilar) anticorps (ABIN7200664)

Antigène: RSV (Palivizumab Biosimilar)

Type d'anticorp: Recombinant Antibody

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp RSV (Palivizumab Biosimilar) est non-conjugé

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Détail du produit anti-RSV (Palivizumab Biosimilar) anticorps

Fonction: Palivizumab Biosimilar, RSV Monoclonal Antibody

Specificité: The monoclonal antibody palivizumab biosimilar specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus).

Attributs du produit: Recombinant Humanized IgG1 Monoclonal Antibody.

Purification: Protein A affinity column

Pureté: > 95% by SDS-PAGE under reducing conditions and HPLC.

Stérilité: 0.2 μm filtered

niveau d'endotoxine: < 1 EU per 1 mg of the protein by the LAL method.

Immunogène: The monoclonal antibody palivizumab biosimilar was produced in the palivizumab biosimilar CHO stable cell line.

Isotype: IgG1 kappa

Information d'application

Indications d'application: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by palivizumab.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 mg/mL

Buffer: PBS, pH 7.4, no stabilizers or preservatives.

Agent conservateur: Without preservative

Conseil sur la manipulation: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.

Date de péremption: 12 months

Détails sur RSV (Palivizumab Biosimilar)

Antigène: RSV (Palivizumab Biosimilar)

Classe de substances: Biosimilar

Sujet: Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.